- Home
- RGLS
as 02-21-2025 4:00pm EST
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 74.0M | IPO Year: | 2012 |
| Target Price: | $10.33 | AVG Volume (30 days): | 815.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.83 - $3.79 | Next Earning Date: | 03-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Regulus Therapeutics Inc. (RGLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hagan Joseph P | RGLS | Chief Executive Officer | Jan 30 '25 | Buy | $1.09 | 50,000 | $54,260.00 | 260,808 | |
| BALTIMORE DAVID | RGLS | Director | Jan 30 '25 | Buy | $1.06 | 19,610 | $20,786.60 | 22,169 | |
| Klassen Preston | RGLS | President & Head of R & D | Jan 13 '25 | Sell | $1.26 | 31,445 | $39,721.32 | 36,055 | |
| CALSADA CRISPINA | RGLS | Chief Financial Officer | Jan 13 '25 | Sell | $1.26 | 43,804 | $55,333.21 | 50,566 | |
| Hagan Joseph P | RGLS | Chief Executive Officer | Jan 13 '25 | Sell | $1.26 | 127,054 | $160,494.61 | 210,808 | |
| Aker Christopher Ray | RGLS | Sr. VP & General Counsel | Jan 13 '25 | Sell | $1.26 | 43,635 | $55,119.73 | 49,546 |
Latest Regulus Therapeutics Inc. News
RGLS Breaking Stock News: Dive into RGLS Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently
PR Newswire
18 days ago
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 02/03/2025
Simply Wall St.
20 days ago
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00
GuruFocus.com
24 days ago
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data
MT Newswires
24 days ago
Regulus Therapeutics Kidney Disease Treatment Shows Response in Early-stage Trial -- Shares Fall
PR Newswire
24 days ago
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Simply Wall St.
2 months ago
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns
Compare RGLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGLS Regulus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.